Johnson & Johnson

Latest Headlines

Latest Headlines

J&J stakes out Boston/Cambridge HQ for new innovation center

J&J is about to make a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs in Kendall Square for one of its four global innovation centers--putting it right in the heart of one of the busiest biotech regions in the world.

J&J's DePuy recalls knee component over risk of limb loss

Johnson & Johnson's DePuy unit is recalling the diaphyseal sleeve shipped with its Limb Preservation System, warning that the sleeve may fracture as patients walk, possibly resulting in infection or loss of limb.

Stryker sued over metal-hip safety shortfalls

An Iowa woman is suing Stryker for safety problems over Stryker's now-recalled Rejuvenate metal-on-metal hip implant.

Abbott inks companion Dx deal for J&J's 'breakthrough' cancer drug

Johnson & Johnson scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and now Abbott Laboratories is stepping in to develop a companion diagnostic for the headline-grabbing compound.

J&J braces international market for more metal hip problems

Already reeling from thousands of lawsuits in the U.S. over faulty ASR-model hips, J&J is now warning doctors overseas to stop using another implant it once sold because of reliability issues.

Attorneys: J&J knew of mesh problems before marketing

Johnson & Johnson is facing thousands of lawsuits over its Prolift vaginal mesh implant, and lawyers for the plaintiffs say the company was warned of problems with the devices long before it chose to sell them anyway.

J&J scores 'breakthrough' status at FDA with cancer drug ibrutinib

Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib.

J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib

J&J and Pharmacyclics nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year.

J&J metal hip trial stirs up renewed call for 510(k) reform

A San Francisco Chronicle story renews calls for the FDA to close loopholes that allow devices such as all-metal artificial hips to win 510(k) clearance, and avoid human testing before approval as a result.

EU's biggest drugmakers team up in €196M discovery effort

Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report